V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

EUROPEAN COMMISSION

Prior notification of a concentration

(Case COMP/M.6969 — Valeant Pharmaceuticals International/Bausch & Lomb Holdings)

(Text with EEA relevance)

(2013/C 196/04)

- 1. On 1 July 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (¹) by which Valeant Pharmaceuticals International, Inc. ('Valeant'), a publicly held company established under the laws of Canada, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Bausch & Lomb Holdings Incorporated ('Bausch & Lomb'), a privately held company headquartered in Rochester, NY, USA, by way of purchase of shares.
- 2. The business activities of the undertakings concerned are:
- for Valeant: development, manufacturing and marketing of specialty pharmaceutical products primarily in the areas of dermatology, neurology and branded generics,
- for Bausch & Lomb: development, manufacturing and marketing of ophthalmic, surgical and consumer vision products.
- 3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.
- 4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6969 — Valeant Pharmaceuticals International/Bausch & Lomb Holdings, to the following address:

European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

⁽¹⁾ OJ L 24, 29.1.2004, p. 1 (the 'EC Merger Regulation').